You just read:

Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 66th Annual Meeting of the American Academy of Neurology

News provided by

Upsher-Smith Laboratories, Inc.

Apr 29, 2014, 03:00 ET